Explore

Trendline Trendline
Xenetic Biosciences Presents Promising Data on DNase I Enhancing CAR-T Cell Therapy at ASCO 2026

Xenetic Biosciences Presents Promising Data on DNase I Enhancing CAR-T Cell Therapy at ASCO 2026

Xenetic Biosciences Presents Promising Data on DNase I Enhancing CAR-T Cell Therapy at ASCO 2026
Rapid Read Rapid Read
Penn Medicine Research Suggests Weight Loss Drugs May Prevent Breast Cancer

Penn Medicine Research Suggests Weight Loss Drugs May Prevent Breast Cancer

Preliminary research from Penn Medicine indicates that popular weight loss drugs, including Ozempic and Wegovy, may have the potential to prevent breast cancer. The study, led by Penn Medicine researchers, suggests that these medications could play a role in reducing breast cancer risk, although the exact mechanisms remain unclear. The research is still in its early stages, and while the findings are promising, they require further investigation to confirm the potential benefits and understand how these drugs might contribute to cancer prevention.
Rapid Read Rapid Read
Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T therapy, LB2501, has achieved a 100% response rate in a Phase 1 study of non-Hodgkin lymphoma. All six patients treated with the therapy responded, with five achieving complete remission. The study's results position Legend Biotech as a potential takeover target in the competitive CAR T market. The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported. The trial is ongoing, with further data expected in the coming years.
Rapid Read Rapid Read
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for Sickle Cell Disease Therapy

CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for Sickle Cell Disease Therapy

CorrectSequence Therapeutics, a biotechnology company, has announced promising results from a clinical trial involving its high-precision base-editing therapy, CS-206, for sickle cell disease (SCD). The therapy has shown efficacy in preventing vaso-occlusive crises (VOCs) and anemia in a patient for over 15 months post-treatment. CS-206 utilizes transformer Base Editing (tBE) technology to precisely edit the HBG1/2 promoter region in hematopoietic stem cells, increasing fetal hemoglobin levels and reducing sickle hemoglobin. This approach offers advantages over CRISPR-based therapies by avoiding DNA double-strand breaks, thus minimizing risks of genomic deletions and mutations. The therapy has demonstrated rapid hematopoietic recovery and significant reduction in red blood cell sickling.
Trendline Trendline
AvenCell Therapeutics to Present Phase 1a Results of CAR-T Therapy for AML

AvenCell Therapeutics to Present Phase 1a Results of CAR-T Therapy for AML

AvenCell Therapeutics to Present Phase 1a Results of CAR-T Therapy for AML
Rapid Read Rapid Read
MEDSIR's New Therapeutic Strategy Shows Promise in Advanced Prostate Cancer Treatment

MEDSIR's New Therapeutic Strategy Shows Promise in Advanced Prostate Cancer Treatment

MEDSIR, an international oncology research company, has presented the final results of its ZZ-FIRST study at the ASCO scientific congress in Chicago. The study explores a new therapeutic strategy for patients with high-volume metastatic hormone-sensitive prostate cancer. This approach combines enzalutamide, a next-generation hormonal treatment, with talazoparib, a PARP inhibitor, to intensify standard therapy. The goal is to block tumor progression before the cancer develops resistance to treatment. The study enrolled 54 patients from Spanish centers and demonstrated that the combination therapy resulted in a radiographic progression-free survival of 45.3 months, compared to 31.1 months with enzalutamide alone. This suggests a significant improvement in delaying tumor progression.
Rapid Read Rapid Read
Researchers Identify microRNA-25 as Key to Overcoming Immunotherapy Resistance in Cancer

Researchers Identify microRNA-25 as Key to Overcoming Immunotherapy Resistance in Cancer

Researchers at the University of California San Diego have identified microRNA-25 (miR-25) as a significant factor in the resistance of tumors to immunotherapy. The study, conducted on mouse cancer models, demonstrated that deleting miR-25 sensitizes tumors to immune checkpoint therapy, a form of treatment that helps the immune system recognize and attack cancer cells. The research highlights miR-25's role in creating a treatment-resistant environment by being upregulated in melanoma cell lines and patient samples, contributing to hypoxia-driven immunosuppression. The study utilized CRISPR-Cas9 to knock out the Mir25 gene in various mouse cancer cell lines, which improved the tumors' response to immune checkpoint therapy. This discovery points to the miR-25-SDC3 pathway as a potential target for future therapeutic interventions, aiming to convert 'cold' tumors into more treatment-responsive 'hot' tumors.
Trendline Trendline
NewLimit Secures $435 Million for Age-Reversal Clinical Trials

NewLimit Secures $435 Million for Age-Reversal Clinical Trials

NewLimit Secures $435 Million for Age-Reversal Clinical Trials
Trendline Trendline
Corrixr Therapeutics Appoints New CEO to Advance Cancer Treatment Program

Corrixr Therapeutics Appoints New CEO to Advance Cancer Treatment Program

Corrixr Therapeutics Appoints New CEO to Advance Cancer Treatment Program
Trendline Trendline
Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position
Rapid Read Rapid Read
Johnson Johnson's Erleada Shows Promising Results in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promising Results in Prostate Cancer Treatment

A recent study presented at the ASCO conference revealed that Johnson & Johnson's drug Erleada (apalutamide) significantly improves outcomes for patients undergoing radical prostatectomy for high-risk localized prostate cancer. The study involved 2,109 participants and demonstrated that adding Erleada to the standard treatment regimen increased the likelihood of a complete or nearly complete response from 1% to 8.9%. Additionally, patients experienced a 29% lower risk of recurrence and a 20% lower risk of metastasis, with a median survival of 57.1 months compared to 38.4 months in the control group. The trial, which is the largest of its kind, suggests that Erleada could set a new standard for treating this type of cancer.
Rapid Read Rapid Read
New Hormone Regimen May Improve Outcomes for Prostate Cancer Surgery Patients

New Hormone Regimen May Improve Outcomes for Prostate Cancer Surgery Patients

A recent phase 3 clinical trial, known as the PROTEUS trial, has revealed promising results for prostate cancer patients undergoing surgery. Traditionally, patients with high-risk prostate cancer that has not spread have two main treatment options: surgical removal of the prostate or a combination of radiation therapy and hormone therapy. The trial suggests a third option, combining two hormone therapies both before and after surgery, which has shown to be superior to the existing method of using just one hormone therapy. This development is being hailed by some oncologists as a potential new standard of care, with Emmanual Antonarakis, a genitourinary medical oncologist at the University of Minnesota, describing it as a 'watershed moment' in prostate cancer treatment.